Ovarian Cancer | Tumor

CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.

Michelle's Ovarian Cancer Story

April 21st 2017, 12:10am

Video

Challenges in Ovarian Cancer Detection

April 21st 2017, 12:10am

Video

About Ovarian Cancer

April 21st 2017, 12:10am

Video

Expert Discusses Surgery's Evolving Role in Ovarian Cancer

April 10th 2017, 8:44pm

Article

Shana Wingo, M.D., discusses surgery's changing role in the treatment of ovarian cancer.

PARP Inhibitors Continue to Change Ovarian Cancer Treatment

April 5th 2017, 8:33pm

Article

PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.

Zejula Granted FDA Approval for Ovarian Cancer

March 28th 2017, 12:01am

Article

The FDA has approved Zejula (niraparib) for treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the maintence setting.

New Trial Suggests Maintenance Chemotherapy Does Not Aid Overall Survival

March 17th 2017, 6:45pm

Article

Results from a randomized trial suggest maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy do not improve overall survival rates among women with ovarian cancer who had achieved remission.

Hormonal Maintenance Therapy Improves Progression-Free Survival in Ovarian Cancer

March 16th 2017, 8:24pm

Article

Hormonal maintenance therapy may be able to improve PFS rates for some patients with ovarian cancer, according to a recent study.

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

March 15th 2017, 9:19pm

Article

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improving Survival in BRCA-Proficient Ovarian Cancer

March 15th 2017, 8:20pm

Article

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.